Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Esperion Theraptc (NQ: ESPR )

1.350 -0.010 (-0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,843,019
Open 1.360
Bid (Size) 1.310 (16)
Ask (Size) 1.360 (5)
Prev. Close 1.360
Today's Range 1.310 - 1.380
52wk Range 1.120 - 8.870
Shares Outstanding 28,277,493
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Esperion to Present New Key Science at the American Diabetes Association’s 83rd Scientific Sessions 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Present Additional Analyses from the Landmark CLEAR Outcomes Study at ENDO 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
-76.88%
-76.88%
1 Month
-4.93%
-4.93%
3 Month
-71.99%
-71.99%
6 Month
-78.16%
-78.16%
1 Year
-77.87%
-77.87%

More News

Read More
Analyst Ratings for Esperion Therapeutics
Via Benzinga
Esperion Announces Submission of Supplemental New Drug Applications to U.S. FDA for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Adjournment of 2023 Annual Meeting of Stockholders
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Jefferies Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Therapeutics And 2 Other Stocks Under $3 Insiders Are Aggressively Buying
Via Benzinga
Esperion Reports First Quarter 2023 Financial Results
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Retains Gibson Dunn to Secure $300 Million Payment From DSE; Will Announce First Quarter Financial Results Tuesday, May 9
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in JMP Securities Life Sciences Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion to Participate in Bank of America Securities 2023 Health Care Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That Are Preparing To Pump In Q2
Via Benzinga
Esperion to Report First Quarter 2023 Financial Results May 9, 2023
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Esperion Announces Co-Promotion Agreement With Currax Pharmaceuticals LLC
From Esperion Therapeutics, Inc.
Via GlobeNewswire
7 Very Undervalued Penny Stocks to Buy in April 2023
Via InvestorPlace
Why SeaChange International Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Esperion to Participate in Needham 22nd Annual Virtual Healthcare Conference
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Top 5 Health Care Stocks That Preparing To Pump This Quarter
Via Benzinga
Esperion Announces Closing of $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Esperion Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Esperion Announces $56.7 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
From Esperion Therapeutics, Inc.
Via GlobeNewswire
Buy/Sell: Wall Street's Top 10 Stock Calls This Week - Saturday, March 18
Via Talk Markets
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Are Secretly Monitoring But Not Talking About Yet
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.